Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: a randomized controlled trial.


Journal

The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133

Informations de publication

Date de publication:
Feb 2022
Historique:
pubmed: 13 2 2020
medline: 16 2 2022
entrez: 13 2 2020
Statut: ppublish

Résumé

The pathogenesis of vitiligo is complex and multifactorial, accumulating evidence of increased oxidative stress and reduction in catalase levels in vitiligo patients has been shown, hence, pseudocatalase/superoxide dismutase (PSD) gel has been used as treatment option for vitiligo. To assesses the synergic effect of PSD when combines with Tacrolimus 0.1% ointment A randomized controlled trial that included 49 children with vitiligo with limited area (10% or less). Patients were randomized into two groups: Group 1 (24 patients) were treated only with Tacrolimus 0.1% ointment whereas Group 2 (25 patients) were treated with Tacrolimus 0.1% ointment plus PSD. Degree of repigmentation compared to baseline was assessed at 3, 6, and 9 months. The median age was 10.05 years (range 2-18). The percentages of pigmentation on 3, 6, and 9 months for Group 1 were 23.9%, 40.4%, and 60%, respectively and for Group 2 were 23.2%, 40.7%, and 62.4%, respectively. There was no significant difference according to repigmentation percentages between the two groups ( The results showed that the addition of PSD to Tacrolimus ointment in children with limited vitiligo was not associated with any therapeutic benefit.

Sections du résumé

BACKGROUND BACKGROUND
The pathogenesis of vitiligo is complex and multifactorial, accumulating evidence of increased oxidative stress and reduction in catalase levels in vitiligo patients has been shown, hence, pseudocatalase/superoxide dismutase (PSD) gel has been used as treatment option for vitiligo.
AIM OBJECTIVE
To assesses the synergic effect of PSD when combines with Tacrolimus 0.1% ointment
METHOD METHODS
A randomized controlled trial that included 49 children with vitiligo with limited area (10% or less). Patients were randomized into two groups: Group 1 (24 patients) were treated only with Tacrolimus 0.1% ointment whereas Group 2 (25 patients) were treated with Tacrolimus 0.1% ointment plus PSD. Degree of repigmentation compared to baseline was assessed at 3, 6, and 9 months.
RESULTS RESULTS
The median age was 10.05 years (range 2-18). The percentages of pigmentation on 3, 6, and 9 months for Group 1 were 23.9%, 40.4%, and 60%, respectively and for Group 2 were 23.2%, 40.7%, and 62.4%, respectively. There was no significant difference according to repigmentation percentages between the two groups (
CONCLUSIONS CONCLUSIONS
The results showed that the addition of PSD to Tacrolimus ointment in children with limited vitiligo was not associated with any therapeutic benefit.

Identifiants

pubmed: 32048900
doi: 10.1080/09546634.2020.1729952
doi:

Substances chimiques

Immunosuppressive Agents 0
Ointments 0
pseudocatalase EC 1.11.1.-
Catalase EC 1.11.1.6
Superoxide Dismutase EC 1.15.1.1
Tacrolimus WM0HAQ4WNM

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

146-149

Auteurs

Diala M Alshiyab (DM)

Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Firas A Al-Qarqaz (FA)

Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Jihan M Muhaidat (JM)

Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Yousef S Alkhader (YS)

Department of Public Health, Community Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Ruba F Al-Sheyab (RF)

Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Sala I Jafaar (SI)

Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH